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Abstract: Induced pluripotent stem cells (iPSC) have been the focus of several studies due to their
wide range of application, including in cellular therapy. The use of iPSC in regenerative medicine
is limited by their tumorigenic potential. Extracellular vesicles (EV) derived from stem cells have
been shown to support renal recovery after injury. However, no investigation has explored the
potential of iPSC-EV in the treatment of kidney diseases. To evaluate this potential, we submitted
renal tubule cells to hypoxia-reoxygenation injury, and we analyzed cell death rate and changes
in functional mitochondria mass. An in vivo model of ischemia-reperfusion injury was used to
evaluate morphological and functional alterations. Gene array profile was applied to investigate the
mechanism involved in iPSC-EV effects. In addition, EV derived from adipose mesenchymal cells
(ASC-EV) were also used to compare the potential of iPSC-EV in support of tissue recovery. The
results showed that iPSC-EV were capable of reducing cell death and inflammatory response with
similar efficacy than ASC-EV. Moreover, iPSC-EV protected functional mitochondria and regulated
several genes associated with oxidative stress. Taken together, these results show that iPSC can be an
alternative source of EV in the treatment of different aspects of kidney disease.
Keywords: iPSC; extracellular vesicles; AKI; mitochondria; ROS; kidney
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1. Introduction
Stem cells have been the focus of investigation as a therapeutic tool in the treatment of several
diseases, including kidney disorders [1]. Most of the studies investigated the properties of adult stem
cells due to the possibility of isolating these cells from several adult tissues, due to ethical matters,
and due to the low or absent tumorigenic risk associated with pluripotent stem cells [2]. Results
based on the in vivo and in vitro models mimicking acute kidney injury (AKI) have shown that the
presence of bone marrow and tissue-derived mesenchymal stromal cells (MSC) can support renal
recovery, as well as the fact that the main mechanism by which these cells act is through the paracrine
secretion [3,4]. One important component of paracrine secretion is the extracellular vesicles (EV),
a heterogeneous population of small membrane vesicles, consisting of a lipid bilayer that allows
cell-to-cell communication by direct transfer of nucleic acids, proteins, and lipids that can alter the
target cell phenotype [5]. EV have been associated with the regulation of different physiological and
pathological processes, including kidney disease. MSC-derived EV (MSC-EV) actions were initially
reported in glycerol-induced AKI models [6]. The beneficial effects of bone marrow MSC-EV were
similar to those observed with the administration of MSC itself, promoting proliferation and conferring
resistance to apoptosis of renal tubular epithelial cells [6,7]. Moreover, MSC-EV were also shown to
have an important role in the treatment of chronic kidney disease (CKD) by reducing inflammation
and tissue damage, maintenance of renal function, and prevention of fibrosis [8,9].
In this context, the EV open a new perspective in the use of the induced pluripotent stem cells
(iPSCs) and its use in regenerative medicine. Yamanaka and colleagues demonstrated the possibility of
reprogramming a somatic cell to a pluripotent cell state through the transfection of the octamer-binding
transcription factor 3/4 (Oct3/4), sex determining region Y-box 2 (Sox2), Kruppel-like factor 4 (Klf4),
and cellular- master regulator of cell cycle entry and proliferative metabolism (c-Myc) genes [10].
Numerous studies have used this technology to promote investigations related to cell differentiation
processes or even as a platform for highly specific pharmacological tests [11]. However, little is
known about the potential of iPSCs in promoting renal tissue regeneration. Lee and co-workers
demonstrated that iPSC can protect the kidney through the induction of anti-inflammatory, antioxidant,
and anti-apoptotic mechanisms in an ischemia-reperfusion injury (IRI) model [12]. In addition, iPSC
can release EV that carry molecules with cardioprotective properties, thus overcoming—for the first
time—the negative effects of classical cell therapy associated with tumorigenesis [13]. With greater
potential for self-renewal and expansion in culture compared to adult and progenitor stem cells, iPSCs
may represent an interesting and viable source of EV production for the use in the treatment of kidney
diseases. The aim of this study was to evaluate the protective and regenerative potential of EV from
iPSC (iPSC-EV) and understand the mechanisms involved in these processes to explore the use of iPSC
as a tool in regenerative medicine for kidney disease treatment.
2. Materials and Methods
2.1. Cell Culture
Human renal proximal tubule epithelial cells (RPTEC) – HK-2 cells from American Type Culture
Collection (ATCC; Manassas, VA, USA) were used for in vitro experiments. The cells were cultured in
Keratinocyte Serum-Free Medium (K-SFM) medium with 5% fetal calf serum (FCS; Thermo Fisher
Scientific, Waltham, MA, USA) (5% CO2 in air at 37 ◦C). During the injury assays, cells were maintained
in low-glucose Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) in the absence of
FCS. Because MSC-EV properties are well-described in renal recovery, we used human adipose-derived
mesenchymal stromal cells (ASC; Lonza, Basel, Switzerland) and their EV (ASC-EV) to compare with
the effects promoted by iPSC-EV. ASC were cultured in Adipose-Derived Stem Cell Growth BulletKit
Medium (Lonza) (5% CO2 in air at 37 ◦C).
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2.2. iPSC Generation and Characterization
The iPSCs were generated from fibroblast obtained from skin biopsy after informed consent of
healthy donors, according to the protocol previously described in [14], with mild modifications. Briefly,
skin fibroblasts were reprogrammed using the integration-free CytoTune-iPS 2.0 Sendai Reprogramming
Kit (Thermo Fisher Scientific, Waltham, MA, USA), that contains Sendai virus particles bearing the four
Yamanaka factors [15]. About 200,000 cells per well were plated onto a gelatin-coated six-well plate for
24 h prior to viral transduction. The cells were transduced according to the manufacturer’s protocol.
Five days after transduction, cells were plated onto a 10 cm tissue culture plate, previously coated
with 1.5 × 106 mouse embryonic fibroblasts (MEF) cells, and fed with iPS cells’ medium supplemented
with 30 ng/mL freshly added basic fibroblast growth factor (bFGF) (Thermo Fisher Scientific) every
day. About 21 days after plating, well-formed colonies were picked for expansion into individual iPS
cell lines. Hereafter, expansion progressed on Matrigel-coated plates (BD Biosciences, San Jose, CA,
USA). Cells were kept in feeder-free maintenance medium for human embryonic stem cells and iPSC
(mTeSR-1) (StemCell Technologies, Köln, Germany). The experimental protocol was approved by the
research ethics board of the Clementino Fraga Filho University Hospital (38583914.7.0000.5257/933.018,
Rio de Janeiro, Brazil). Another iPSC line was obtained from peripheral blood, according to the protocol
described in [16], and with the approval of the Research Ethics Committee of the National Institute of
Cardiology (27044614.3.0000.5272, Rio de Janeiro, Brazil).
For characterization of iPSC, qRT-PCR was performed to evaluate the mRNA levels of Sox2,
Oct4, c-Myc, and Nanog homeobox (Nanog) through a High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) and Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA, USA). Negative cDNA controls (no cDNA) were cycled in parallel with each run. qRT-PCR
was performed with a ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
The mRNA levels present in the iPSC were compared to normal human dermal fibroblasts (NHDF;
Lonza). We also evaluated the expression of pluripotency markers by immunofluorescence. The
cells cultivated in coverslips were initially washed twice with 2 mL of ice-cold phosphate-buffered
saline (PBS) and fixed with 4% paraformaldehyde and posteriorly permeabilized with 1% Triton X-100
(Thermo Fisher Scientific). Fixed cells were incubated with blocking solution (10% normal goat serum,
0.1% Tween 20 in PBS) before incubation with primary antibody. The antibodies used for pluripotency
characterization—mouse Oct3/4 (Santa Cruz Biotechnology SC5279, Dallas, TX, USA), mouse
Podocalyxin (TRA-1-60; Merck Millipore MAB4360), and mouse stage-specific embryonic antigen-4
(SSEA4; Merck Millipore MAB4304)—were incubated for 1 h at room temperature (dilution 1:100).
The secondary antibodies (goat anti-mouse immunoglobulin G (IgG) Alexa 488-conjugated, or goat
anti-mouse Alexa 594-conjugated, both from Thermo Fisher Scientific) were incubated with the cells for
2 h at room temperature (dilution 1:200). The nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Coverslips were mounted on glass slides
with Vectashield mounting media (Vector Laboratories, Burlingame, CA, USA) and sealed. Cells were
visualized by using a Zeiss confocal LSM710 microscope (Oberkochen, Germany) provided with the
appropriate laser beams.
2.3. EV Isolation and Characterization
The supernatant from iPSC, cultured for 24 h in mTeSR-1 medium, and ASC, cultured for 24 h
in Roswell Park Memorial Institute (RPMI) medium (Thermo Fisher Scientific, Waltham, MA, USA)
cultures was collected and centrifuged at 300× g, followed by centrifugation of 2000× g for 20 min
to remove cells and debris. The supernatants were ultracentrifuged at 100,000× g (Optima L-90K
ultracentrifuge; Beckman Coulter, Brea, CA, USA) for 2 h at 4 ◦C, and the pellets were then resuspended
in RPMI and submitted to the second ultracentrifugation at 100,000× g, for 2 h at 4 ◦C. The final pellet
containing ASC-EV or iPSC-EV were resuspended in RPMI and stored at −80 ◦C in aliquots. The
characterization of EV was performed in accordance with the MISEV 2018 guidelines [17]. The size
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and number of isolated EV were analyzed by a ZetaView-Nanoparticle Tracking Video Microscope
PMX-120 instrument (Particle Metrix, Germany).
Transmission electron microscopy (TEM) was performed to characterize the iPSC-EV. Isolated
iPSC-EV resuspended in PBS adhered onto glow-discharged formvar-coated copper grids 300 mesh
(EMS, Hatfield, PA, USA) for 10 min. After removal of excess solution using Whatman no. 1 filter
paper (Thermo Scientific), grids were negatively stained with 1% aurothioglucose (USP) in water for
30 s, dried, and examined in a Tecnai-Spirit TEM (Thermo Scientific).
An initial characterization of iPSC-EV markers was performed by using an ExoView Tetraspanin
Kit (NanoView Bioscience, Boston, MA, USA). Each chip was coated with CD9, CD81, CD63, CD105,
CD44 antibodies and MIgG, MIgG2a, MIgG2b control antibodies. The chips were incubated with
different EV samples overnight, and protected from the light by using 35µL of EV suspension diluted
at 1:100. After multiple washing steps, the chips were analyzed in ExoView R100 imaging platform
(NanoView Bioscience, Boston, MA, USA). Further characterization of iPSC-EV markers was performed
using the bead-based multiplex exosome flow cytometry assay (MACSPlex Exosome Kit human,
Miltenyi Biotec, Bergisch Gladbach, Germany). Shortly after, samples were diluted with the MACSPlex
buffer to a final concentration of 4–20 µg of protein and a final volume of 120 µL. A total of 15 µL of
the MACSPlex Exosome Capture beads, which contain 39 different antibody-coated beads, and 15 µL
of MACSPlex Exosome Detection Reagent cocktail, was added. After the incubation of 1 h at room
temperature while being protected from the light on an orbital shaker, 1 mL of MACSPlex buffer was
added and all samples were centrifuged at room temperature at 3000× g for 5 min. Then, the samples
were washed with 1 mL of the MACSPlex, and incubated at room temperature protected from the
light on an orbital shaker for 15 min followed by a wash at 3000× g for 5 min. A total of 150 µL of the
samples were transferred to the flow cytometry tubes and characterized by using BD FACSCelesta
flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Western blot analysis was also performed on EV previously lysed in Radioimmunoprecipitation
(RIPA) buffer (Sigma-Aldrich, St. Louis, MO, USA) using the following primary antibodies: CD63
(sc-5275; 1:50; Santa Cruz Biotechnology, Dallas, TX, USA) and CD81 (sc-70803; 1:50; Santa Cruz
Biotechnology). The secondary antibody anti-mouse IgG-horseradish peroxidase (HRP) (NA931,
1:10,000; GE Healthcare, Buckinghamshire, United Kingdom) was used, and proteins were detected by
chemiluminescence using the electrogenerated chemiluminescence (ECL) system (GE Healthcare) and
ChemiDoc XRS+ (Bio-Rad, Hercules, CA, USA).
2.4. In Vitro Injury Model and Cell Death Analysis
RPTEC were incubated with K-SFM medium with 5% FCS until reaching 70–80% confluence.
The cells were then washed three times with PBS and cultured in low-glucose DMEM with no FCS
for 24 h under hypoxic condition (37 ◦C, 1% O2, 5% CO2) without (HPX) or with the presence of EV
(HPX+ASC-EV or HPX+iPSC-EV), 1.2 × 104 vesicles per renal cell. Lower amounts of EV were tested,
but no effect was observed (data not shown). After this period, the RPTEC were cultured for another
24 h under normal culture condition (37 ◦C, 21% O2, 5% CO2) to mimic the reperfusion phase. For
control condition (CTR), the RPTEC were cultured in low-glucose DMEM with no FCS for 48 h under
normal culture condition (37 ◦C, 21% O2, 5% CO2). The cell death analysis was performed using a
Dead Cell Apoptosis Kit with annexin V fluorescein isothiocyanate (FITC) and propidium (PI) (Thermo
Fisher Scientific) and fluorescent intensity was measured by flow cytometry with a BD Accuri C6 Plus
instrument with CFlow Plus software (BD Biosciences, San Jose, CA, USA).
2.5. Measurement of Functional Mitochondrial Mass inside RPTEC
To measure the mitochondrial mass and membrane potential (∆Ψm), we used MitoTracker
Mitochondrion-Selective Probes. To evaluate the alterations in mitochondrial mass inside the cells, we
used MitoTracker Green FM, a fluorescent dye that stains mitochondria. In addition, to evaluate the
loss of ∆Ψm, we used the MitoTracker Orange CMTMRos, a fluorescent dye that accumulates only in
Cells 2020, 9, 453 5 of 20
mitochondria that present intact ∆Ψm. After RPTEC were submitted to their respective experimental
conditions (CTR, HPX, HPX+iPSC-EV, HPX+ASC-EV), the cells were washed three times with PBS
and then harvested. The cells from each condition were divided into three groups for staining: (i) 15
min incubation with 50 nM MitoTracker Green FM dye; (ii) 15 min incubation with 50 nM MitoTracker
Orange CMTMRos dye; and (iii) no dye, as a negative control. After incubation, cells were washed with
PBS, and fluorescent intensity was measured by flow cytometry with a BD Accuri C6 Plus instrument
and CFlow Plus software (BD Biosciences).
2.6. AKI In Vivo Model
The animal experiments were approved by the Ethics Committee on the Use of Animals in
Scientific Experimentation of Federal University of Rio de Janeiro (Protocol 043/19). Male Wistar rats
(200–250 g) were purchased from the Animal Facility of the Institute of Biomedical Sciences of the
University of São Paulo, São Paulo, Brazil. Before surgical procedures, the animals were anaesthetized
by intraperitoneal injection of xylazine (Bayer S.A., São Paulo, Brazil; 5 mg/kg) and ketamine (Cristália,
Itapira, Brazil; 50 mg/kg) [18]. The animals were distributed into four groups: (1) the SHAM group—the
rats were submitted to surgical procedures without the ischemic injury; (2) the IRI group—the rats
were submitted to bilateral renal arterial clamping (45 min) followed by reperfusion with immediate
subcapsular injection of PBS into each kidney after removal of the clamps; (3) the IRI+ iPSC-EV
group—the rats were submitted to bilateral renal arterial clamping and received subcapsular injection
on both kidneys of 1 × 109 EV derived from iPSC at the beginning of reperfusion in each kidney; (4) the
IRI+ASC-EV group—the rats were submitted to the same surgical procedures followed by subcapsular
injection into each kidney of 1 × 109 EV derived from ASC. The doses of EV were defined on the basis
of previous works [8,18,19] and from other works wherein MSC-EV promoted protective effects in
different kidney injury models. The subcapsular injection was chosen to observe a direct effect of
EV in the kidney and to guarantee the delivery of the entire amount of EV. After 72 h, the animals
were euthanized by intraperitoneal injection of a high dose of xylazine (30 mg/kg) and ketamine
(200 mg/kg). The 72 h reperfusion period was shown to promote renal tissue damage, where changes in
the architecture and trigger in the inflammatory response could be observed [18]. For kidney functional
analysis, blood samples were collected for measurement of blood urea nitrogen (BUN) and creatinine
by using the respective kits for colourimetric assays (Bioclin, Belo Horizonte, Brazil) [18]. The kidneys
were collected and processed for histological and molecular analysis.
2.7. Histological Analysis
To evaluate tubular damage in the kidneys, 5 µm-thick paraffin kidney sections were stained
with hematoxylin and eosin (Sigma-Aldrich). Images (20× objective) were taken from 15 fields of
each kidney, and the tubular injury was analyzed by the number of luminal hyaline casts and number
of tubules that presented denudation of basement membrane in the cortical region [20]. The injury
score was given by the mean of the number of casts and denuded tubule identified in each of the 15
photomicrographs of each kidney.
2.8. Immunohistochemistry Analysis
Immunohistochemistry for cell proliferation and macrophage infiltration was performed using
antibodies against PCNA (Agilent Technologies) and ED-1/CD68 (Bio-Rad), respectively [18]. To
evaluate cell death, apoptosis was measured by Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay (ApopTag Apoptosis Detection Kit; Millipore Inc., Billerica, MA, USA). Sections
were incubated with isotype-specific immunoglobulins as negative controls. Histomorphometry
analyses used a computer-assisted image analysis system (Nikon Eclipse E-800 microscope connected
to a computer by a digital camera Evolution, Media Cybernetics Inc., Tallahassee, FL, USA) coupled
to the software Q-Capture 2.95.0 (Silicon Graphic Inc., Milpitas, CA, USA). A total of 15 high-quality
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photomicrographs were captured from non-overlapping renal cortical region with a 20× or 40×
objective lens.
2.9. RT2 Profiler PCR Array and qRT-PCR Confirmation
Total RNA was isolated from cortical renal specimen using the mirVana RNA isolation kit
(Ambion). The RNA integrity and quality were evaluated using RNA 6000 Nano Chip and Agilent
2100 Bioanalyzer (Agilent Technologies). Only RNA integrity numbers (RINs) >8.0 in the RNA sample
were considered adequate for further studies.
The rat profile analysis was conducted on different experimental groups (n = 3 SHAM; n = 5
IRI; n = 6 IRI+iPSC-EV), pooling together 2-3 animals per treatment. cDNA was then synthesized
from 1 µg of RNA input and the expression of 84 oxidative stress-related genes was examined using
the RT2 Profiler PCR array rat samples (Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions using the Applied Biosystems 7900HT real-time PCR instrument. Data analysis was
performed using Expression Suite software (Thermo Fisher Scientific) and the expression levels of
the mRNA of each gene were normalized using different housekeeping genes – glyceraldehyde
3-phosphate dehydrogenase (GAPDH), Actin-like protein (ACT B), beta-2 microglobulin (B2M), lactate
dehydrogenase A (LDHA), hypoxanthine phosphoribosyltransferase 1 (HPRT1), and ribosomal protein
lateral stalk subunit P1 (RPLP1). Up-regulated or down-regulated transcripts with a fold change ≥ 1.5
with respect to IRI condition (Table S1) were taken into consideration only when observed in more
than two arrays. Functional annotation enrichment analysis was performed using Ingenuity pathway
analysis (IPA) software (Redwood City, CA USA).
To compare the regulatory capacity of iPSC-EV to the ASC-EV, we assessed the mRNA levels
in RPTEC by quantitative real-time PCR using a High Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific) and the Power SYBR Green PCR Master Mix (Thermo Fisher Scientific).
Negative cDNA controls (no cDNA) were cycled in parallel with each run. Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed using a ViiA 7 Real-Time PCR System (Thermo
Fisher Scientific). The sequence-specific oligonucleotide primers were all obtained from MWG-Biotech
AG, Ebersberg, Germany (www.mwg-biotech.com) (Table S2).
2.10. Statistical Analysis
Statistical analyses used the Student t-test or the one-way analysis of variance (ANOVA) test with
Tukey’s post-test. Statistical significance was set at p < 0.05. Data were analyzed using the GraphPad
Prism 5.0 program. The data are expressed as mean ± standard error of the mean (SEM).
3. Results
3.1. Pluripotency of iPSC Were Maintained during EV Collection
The collection of iPSC-EV was made with the supernatant of iPSC cultured for 24 h. To confirm
the pluripotency state of the cell under our culturing protocol, we evaluated the pluripotency markers
by qRT-PCR in comparison to NHDF. The obtained results showed that all three iPSC lines presented
elevated mRNA levels of the pluripotency markers (Sox2, Oct4, c-Myc, and Nanog) that were
absent in NHDF (Figure 1A). Immunofluorescent characterization was also performed to confirm the
pluripotency state of iPSC (Figure 1B). The iPSC were positive for Oct4, TRA-1-60, and SSEA-4. The
last two makers were originally described in embryonal carcinoma cells and are considered makers for
iPSC characterization [21]. With these results, we could confirm that the EV collected were derived
from iPSC.
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column shows the positive staining for OCT4 (upper image) in green, TRA-1-60 (central image) in 
red, and SSEA-4 (lower image) in red. The central column shows the nuclei stained with DAPI in blue. 
The right column shows the overlap of the two previous respective images. (C) Representative 
nanoparticle tracking analysis (NTA) of (left) iPSC-EV isolated (white dots) from the culture 
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Figure 1. Char cterization of induced pl ri e ls (iPSC) and iPSC-derived extracellular
vesicles (iPSC-EV). (A) The graph indicates t l l f transcription factors associated with
pluripotency SOX2, OCT4, C-MYC, and NA OG in iPSC generated from three different do ors (iPSC1,
2, and 3). The ordinate indicates the relative quantification of mRNA levels with respect to normal
human dermal fibroblasts (NHDF). The abscissa indicates the cell types. Data represent mean ± SEM (
* indicates statistical difference to the NHDF group, p <0.05 assessed by one-way ANOVA followed by
Tukey’s test). (B) Immunofluorescent staining of iPSC for pluripotency markers. The left column shows
the positive staining for OCT4 (upper image) in green, TRA-1-60 (central image) in red, and SSEA-4
(lower image) in red. The central column shows the nuclei stained with DAPI in blue. The right column
shows the overlap of the two previous respective images. (C) Representative nanoparticle tracking
analysis (NTA) of (left) iPSC-EV isolated (white dots) from the culture supernatant. The right image
shows the iPSC-EV size distribution and concentration, as indicated in the abscissa (diameter/nm)
and in the ordinate (particles/mL). (D) Electron microscopy images of isolated iPSC-EV in different
magnifications (scale bars = 200 nm). (E) Representative image of western blot of CD63 and CD81
expression in iPSC-EV. (F) Analysis of iPSC-EV markers with MACSPlex Exosome kit. The graph
shows the median fluorescence intensity of each marker, with the background correction. The abscissa
indicates the APC fluorescence intensity levels (n = 4). (G) Correlation between size and positivity for
exosome markers of iPSC-EV. The graph shows in the ordinate the number of vesicles that are positive
for each marker and the abscissa shows the diameter of vesicles. Each condition is indicated on the
right according to the symbol (n = 3).
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The size distribution analysis showed a heterogeneous population of EV produced by iPSC,
ranging from 32 nm to 229 nm, with a mean value of 119 nm (Figure 1C). The EV population isolated
from ASC presented a size distribution that ranged from 47 nm to 211 nm, with a mean value of 125 nm
(data not shown). TEM analysis revealed a classical circular morphology of iPSC-EV and confirmed
the heterogeneous size of the population (Figure 1D). Western blot analysis showed the presence of
exosome markers CD63 and CD81 in the iPSC-EV (Figure 1E). Moreover, a deeper analysis in the
iPSC-EV markers was performed though a wide screening of surface markers by using a bead-based
multiplex exosome flow cytometry assay (Figure 1F). The obtained results confirmed the presence of
classical exosome markers (CD9, CD63, and CD81). Moreover, iPSC-EV were enriched of different
embryonic markers – CD133-1, CD326, SSEA-4, CD24, and Receptor Tyrosine Kinase Like Orphan
Receptor 1 (ROR1) – showing that the EV carry molecules associated with their cell of origin. In order to
better characterize the iPSC-EV, we also performed NanoView analysis, showing the size distribution
of iPSC-EV correlated to its size diameter. The results confirmed the presence of a population of
exosome positive for CD9, CD63, and CD81 with size ranging between a diameter of 50-110 nm. It is
worth mentioning that a small population of iPSC-EV showing positivity for the CD44 marker with
the size ranging from 55 to 85 nm was detected.
3.2. iPSC-EV Promoted a Protective Effect against Hypoxia-Reoxygenation Injury in RPTEC
To evaluate the therapeutic properties of iPSC-EV, we submitted RPTEC cells to hypoxia-
reoxygenation injury (HPX) that mimicked the IRI (Figure 2A). HPX RPTEC presented an increase
in cell death (25% ± 0.4% of dead cells) when compared to the control condition (CTR, 6% ± 0.3% of
dead cells). The presence of iPSC-EV (HPX+iPSC-EV) in the culture led to considerable protection
of RPTEC (11% ± 0.3% of dead cells). Such effect was stronger than the one promoted by ASC-EV
(HPX+ASC-EV), which also promoted a reduction in cell death in comparison with HPX conditoin
(17% ± 0.6% of dead cells).
3.3. Protective Effect of iPSC-EV Was Associated with Maintenance of Functional Mitochondrial Mass
One important aspect of renal tissue damage during IRI is the mitochondria alteration. Because
mitochondrial damage can trigger different cell death pathways and lead to a reduction in the
intracellular ATP levels [22], we wanted to observe if the reduction in cell death rate promoted by
iPSC-EV could be related to the mitochondria protection (Figure 2B,C). Analysis of fluorescence
intensity of RPTEC cells stained with MitoTracker Green FM and MitoTracker Orange CMTMRos
(mitochondrial mass and membrane potential, respectively) revealed that RPTEC presented a reduction
in mitochondrial mass after hypoxia-reoxygenation injury (HPX = 15.1% ± 1.7% of total cells) when
compared to CTR cells (1.6% ± 0.6% of total cells). The impact of the injury can be better observed
when we analyzed the rate of cells that presented a reduction in ∆Ψm (CTR = 9.1% ± 2.2% of total
cells; HPX = 37.2% ± 5.5% of total cells). Such a result indicated that hypoxia-reoxygenation injury can
directly affect mitochondrial mass, also altering the mitochondrial ∆Ψm inside RPTEC. Incubation
of iPSC-EV partially limited the cells affected by the injury, presenting a significant reduction of
the loss of mitochondrial mass and also of ∆Ψm with respect to HPX condition (mitochondrial
mass—HPX+iPSC-EV = 6.8% ± 1.2% of total cells; ∆Ψm—HPX+iPSC-EV = 22.3% ± 2.9% of total
cells). Such reduction was also observed when RPTEC were incubated with ASC-EV (mitochondrial
mass—HPX+ASC-EV = 6.4% ± 1.3% of total cells; ∆Ψm—HPX+ASC-EV = 20.5% ± 2.7% of total
cells). EV seem to act in a way that protects mitochondria from damage by maintaining functional
mitochondria that can restore cell energy supply, therefore resulting in renal cell survival.
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Analyses of alterations in renal cells’ mitochondria potential (∆Ψm). The panels are representative
flow cytometry analyses of renal cells incubated with the mitochondria fluorescent marker MitoTracker
Orange CMTMRos. The abscissa indicates the distribution of fluorescence intensity given by the
respective mitochondria with intact ∆Ψm. The ordinate indicates the number of events analyzed.
M3 indicates the percentage of cells with reduced fluorescence intensity and, therefore, reduction
in mitochondrial ∆Ψm. The graph in the right shows the percentage of the total cell population
that presented a reduction of mitochondria mass with intact ∆Ψm, as indicated in the ordinate. The
experimental group conditions are indicated in the abscissa (n = 5). Data represent mean ± SEM
(* indicates statistical difference to CTR group; # indicates statistical difference to HPX group; **
indicates statistical difference to HPX+iPSC-EV group; p <0.05 assessed by one-way ANOVA followed
by Tukey’s test).
3.4. iPSC-EV Promoted the Protection of Renal Tissue and Kidney Function in IRI
To assess the role of EV-iPSC in the kidney, we performed in vivo experiments using a bilateral
renal arterial clamping model (Figure 3). Histological analyses of cortical kidney sections revealed that
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animals submitted to IRI presented damaged tubules and accumulation of hyaline casts, which were
both almost absent in SHAM animals, as measured by the injury score (Figure 3A). Administration of
iPSC-EV after removal of the clamping resulted in a 56% reduction of the injury score (IRI+iPSC-EV).
ASC-EV-injected animals also presented a substantial reduction of 40% in renal tissue damage. Although
the iPSC-EV protective effect was stronger, no significant difference was observed between the two
animal groups treated with EV.
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Figure 3. Subcapsular injection of iPSC-EV promoted the protection of renal tissue against ischemia-
reperfusion injury (IRI). (A) Representative photomicrographs show the kidney cortical sections stained
with hematoxylin/eosin (H/E) in the different experimental conditions (scale bar = 100 µm). From the
left i age to the right: SHAM indicates false-operated animals; IRI represents the animals submitted
to ischemia-reperfusion injury by the bilateral renal arterial clamping; IRI+iPSC-EV indicates the
animals submitted to renal ischemia and that received subcapsular injection of iPSC-EV into the kidney
just after the clamp release; IRI+ASC-EV indicates the animals submitted to renal ischemia and that
received subcapsular injection of ASC-EV into the kidney just after t clamp release. The graph
shows the score of tubular lesions in each conditi . SHAM, n (kidneys) = 4; IRI, n (kidneys) = 8;
IRI+iPSC-EV, n (kidneys) = 16; IRI+ASC-EV, n (kidneys) = 6. (B) Representative photomicrographs of
immunohist chemi try for PCNA (scale bar = 100 µm). The gr ph in the right shows the quantification
of the number of PCNA-posi ive cells per field from immunohistochemist y. SHAM, n = 10 fields for
6 kidneys; IRI, n = 10 fields for 7 kidneys; IRI+iPSC-EV, n = 10 fields for 16 kidneys; IRI+ASC-EV,
n = 10 fields for 6 kidneys. (C) Repres ntative photomicrographs of immunohistochemistry f r TUNEL
(scale bar = 50 µm). The graph in the right shows the quantification of the number of TUNEL-positive
cells per field from immunohistochemistry. SHAM, n = 10 fields for 6 kidneys; IRI, n = 10 fields for
7 kidneys; IRI+iPSC-EV, n = 10 fields for 16 kidneys; IRI+ASC-EV, n = 10 fields for 6 kidneys. Data
represent mean ± SEM (* indicates statistical difference to SHAM group; # indicates statistical difference
to IRI group; ** indicates statistical difference to IRI+iPSC-EV group; p <0.05 assessed by one-way
ANOVA followed by Tukey’s test).
The evaluation of cell death rate was measured by the quantification of TUNEL-positive cells
in cortical kidney sections (Figure 3B). The kidneys of IRI animals showed a significant increase
in the number of dead tubular cells with respect to SHAM (SHAM = 5.1 ± 0.2 TUNEL-positive
cells/field; IRI = 17.1 ± 0.5 TUNEL-positive cells/field). The subcapsular injection of iPSC-EV promoted,
also in the in vivo model, a consistent reduction in the number of dead cells (IRI+iPSC-EV =
6.8 ± 0.2 TUNEL-positive cells/field). Such an effect was stronger than the one observed by ASC-EV
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administration (IRI+iPSC-EV = 9.9 ± 0.5 TUNEL-positive cells/field), although the last treatment was
still effective in the reduction of tubular cell death.
A similar response was also observed when the proliferative rate in renal tubular cells was analyzed
(Figure 3C). Because IRI promoted cell death and tissue damage, the proliferative response associated
with the renal tissue attempt to recover resulted in the increase in the number of PCNA-positive tubular
cells in the cortical region of kidney (IRI = 59.5 ± 0.9 PCNA-positive cells/field) when compared with
SHAM group (SHAM = 4.9 ± 0.2 PCNA-positive cells/field). Administration of iPSC-EV and ASC-EV
resulted in a significant reduction in the number of proliferating cells (IRI+iPSC-EV = 42.5 ± 0.9
TUNEL-positive cells/field; IRI+ASC-EV = 41.1 ± 0.9 TUNEL-positive cells/field). Such results indicate
that the decrease of proliferative rate was associated with the tissue protection mediated by iPSC-EV.
Analyses of renal function were assessed by the measurement of creatinine and BUN levels in
the blood (Figure 4). The animals submitted to IRI presented increased and pathological levels of
blood creatinine and BUN, indicating a reduction in kidney function when compared with SHAM
group. Injection of iPSC-EV promoted significant conservation of kidney functions, as observed by the
reduction of both parameters. The same was observed when ASC-EV were administered subcapsularly
and no statistical difference was observed between iPSC-EV and ASC-EV groups.
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± SEM (* indicates statistical difference to SHAM group; # indicates statistical difference to IRI group; 
p <0.05 assessed by one-way ANOVA followed by Tukey’s test). 
3.5. iPSC-EV Promote the Reduction in Macrophage Infiltration 
Macrophages are critical elements in the inflammatory response associated with IRI, and we 
aimed to see if iPSC-EV could also contribute to the reduction of macrophage infiltration (Figure 5). 
We analyzed the number of macrophage (ED-1-positive cells) presented in the renal tissue in the 
different experimental conditions (Figure 5A,B). A small number of ED-1-positive cells were 
identified in the kidney of SHAM group (SHAM = 4 ± 0.3 ED-1-positive cells/field), whereas IRI 
Figure 4. Administration of iPSC-EV after ischemia promoted the protection of kidney function.
(A) Measurement of blood urea nitrogen (BUN) levels of the animals submitted to the different
experimental conditions. The abscissa indicates each experimental groups: SHAM, IRI, IRI+iPSC-EV,
and IRI+ASC-EV. The ordinate indicates the concentration of BUN (mg/dL). (B) Measurement of
creatinine levels in the blood of the animals submitted to the different experimental conditions, as
indicated in the abscissa. The ordinate indicates the creatinine concentration in the blood (mg/dL).
In both analyses, SHAM, n = 4; IRI, n = 5; IRI+iPSC-EV, n = 11; IRI+ASC-EV, n = 5. Data represent
mean ± SEM (* indicates statistical difference to SHAM group; # indicates statistical difference to IRI
group; p <0.05 assessed by one-way ANOVA followed by Tukey’s test).
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3.5. iPSC-EV Promote the Reduction in Macrophage Infiltration
Macrophages are critical elements in the inflammatory response associated with IRI, and we
aimed to see if iPSC-EV could also contribute to the reduction of macrophage infiltration (Figure 5). We
analyzed the number of macrophage (ED-1-positive cells) presented in the renal tissue in the different
experimental conditions (Figure 5A,B). A small number of ED-1-positive cells were identified in the
kidney of SHAM group (SHAM = 4± 0.3 ED-1-positive cells/field), whereas IRI resulted in a noteworthy
increase in the number of infiltrating macrophages (IRI = 37.9 ± 6.1 ED-1-positive cells/field). As a
result of iPSC-EV administration, the number of macrophages significantly decreased (IRI+iPSC-EV
= 18.3 ± 0.9 ED-1-positive cells/field). ASC-EV also led to a significant reduction in the number of
infiltrated macrophages (IRI+ASC-EV = 24.4 ± 1.8 ED-1-positive cells/field). In order to understand if
the macrophages accumulated in the kidney had a pro-inflammatory role, we analyzed the mRNA
levels of inducible nitric oxide synthase (iNOS), expressed in M1-polarized macrophages and the
mRNA levels of macrophage mannose receptor (CD206), known to be upregulated in M2-polarized
macrophage. The obtained results showed that mRNA levels of iNOS presented a 200-fold increase in
the renal tissue submitted to IRI with respect to SHAM condition (Figure 5C). Treatment with iPSC-EV
was able to completely abrogate this increase. The ASC-EV were as efficient as iPSC-EV, resulting in
mRNA levels reduced almost to the levels found in SHAM. The CD206 mRNA levels were shown to
be increased in the kidney after IRI (≈3-fold increase with respect to SHAM group), and the treatment
with iPSC-EV after ischemic insult led to a stronger increase (≈2.4-fold in respect to IRI) (Figure 5D).
In this case, CD206 was also upregulated in ASC-EV-treated rats, but they did not show statistical
differences with respect to the IRI group (≈1.4- fold increase with respect to IRI). ASC-EV were also able
to reduce the mRNA levels of iNOS; however, the increase of mRNA of CD206 was not significantly
different with respect to IRI (Figure 5C,D, respectively). Such results indicate that macrophages were
present in the renal tissue after IRI showed a pro-inflammatory phenotype.
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3.6. iPSC Promoted Kidney Protection through Reduction of Oxidative Stress after IRI 
Oxidative stress is one of the main causes of kidney damage during IRI. Gene array analysis of 
kidney tissue revealed that iPSC-EV can modulate different genes associated with an oxidative stress 
response to IRI (Figure 6). We performed Gene Ontology (GO) enrichment analysis to determine the 
significant biological pathways associated with target genes modified by iPSC-EV treatment. As 
Figure 5. iPSC-EV promoted the reduction of the infla matory response induced by IRI. (A)
Representative photomicrographs of the renal tissue stained for ED-1 by immunohistochemistry.
From the left image to the right: SHAM, IRI, IRI+iPSC-EV, and IRI+ASC-EV (scale bars = 100 µm).
(B) Quantification of the number of CD68-positive cells/field. SHAM, n = 10 fields for 4 kidneys; IRI,
n = 10 fields for 5 kidneys; IRI+iPSC-EV, n = 10 fields for 8 kidneys; IRI+ASC-EV, n = 10 fields for 4
kidneys. (C) mRNA levels of iNOS and (D) CD206 in renal tissue expressed as relative quantification
(RQ) with respect to the IRI group (SHAM, n = 3; IRI, n = 3; IRI+iPSC-EV, n = 5; IRI+ASC-EV, n = 3).
Data represent mean ± SEM (* indicates statistical difference to SHAM group; # indicates statistical
differe ce to IRI group; ** in icates statistical difference to IRI+iPSC-EV group; p <0.05 assessed by
one-way ANOVA followed by Tukey’s test).
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3.6. iPSC Promoted Kidney Protection through Reduction of Oxidative Stress after IRI
Oxidative stress is one of the main causes of kidney damage during IRI. Gene array analysis of
kidney tissue revealed that iPSC-EV can modulate different genes associated with an oxidative stress
response to IRI (Figure 6). We performed Gene Ontology (GO) enrichment analysis to determine
the significant biological pathways associated with target genes modified by iPSC-EV treatment.
As shown in Figure 6a, the group of genes modulated by iPSC-EV were mainly associated with
molecular functions such as glutathione redox reactions, Nuclear factor erythroid 2-related factor 2
(NRF2)-mediated oxidative stress response, superoxide radical degradation, mitochondrial dysfunction,
sirtuins pathways, and endothelin-1 signalling (Figure 6a), which are likely involved in the renal
metabolic response during IRI [23].
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Figure 6. The protective effect of iPSC-EV was related to the modulation of anti-oxidative stress
genes in renal tissue. The analysis performed using Ingenuity pathway analysis (IPA) showed (a)
the enriched biological processes associated with the modulated genes by iPSC-EV administration,
indicated in the horizontal bars and ordered by their significance. (b) IPA network analysis generated
by the modulated genes by iPSC-EV in renal tissue interconnected with relevant nodes involved in
the most representative biological pathways associated with the EV treatment. qRT-PCR analysis of
mRNA levels of (c) superoxide dismutase 1 (SOD1), (d) aldehyde oxidase-1 (AOX1), (e) significantly
up-regulate sirtuin 1 (SIRT1), and (f) SIRT2 in renal tissue expressed as relative quantification (RQ)
with respect to IRI (SHAM, n = 3; IRI, n = 3; IRI+iPSC-EV, n = 5; IRI+ASC-EV, n = 3). Data represent
mean ± SEM (* indicates statistical difference to SHAM group; # indicates statistical difference to IRI
group; ** indicates statistical difference to IRI+iPSC-EV group; p <0.05 assessed by one-way ANOVA
followed by Tukey’s test).
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In particular, the administration of iPSC-EV after ischemic insult resulted in an increase, in two
iPSC-EV sources over three tested, of genes associated with the protection against the oxidative stress:
glutathione S-transferase kappa 1 (GSTK1), selenoprotein P (SEPP1), superoxide dismutase 1 (SOD1),
SOD3, thioredoxin 1 (TXN1), and thioredoxin reductase 2 (TXNRD2) (Figure 6b). All these genes were
reduced in the IRI group with respect to the SHAM group, showing the impairment of the capacity
of renal tissue to process the reactive oxygen species (ROS) during the occurrence of the ischemic
damage (Table 1). Other genes such as iNOS, Nicotinamide-adenine dinucleotide phosphate (NADPH)
oxidase organizer 1 (NOXO1), lactoperoxidase (LPO), and the dual oxidase 1 (DUOX1), associated
with the formation of reactive oxygen species, resulted as being negatively regulated by iPSC-EV
treatment with respect to IRI (Table 1). In order to compare the capacity of iPSC-EV and ASC-EV to
regulate the genes associated with oxidative stress protection, we performed qRT-PCR analysis of
selected genes. Obtained data showed that IRI strongly reduced SOD1 levels with respect to SHAM.
Although both iPSC-EV and ASC-EV showed the capability to induce SOD1 expression, only the
ASC-EV treatment reached significance (iPSC-EV, RQ = 1.5 and ASC-EV = 2.1 with respect to the IRI
group) (Figure 6c). We also tested the expression of aldehyde oxidase-1 (AOX1), a Nrf2-dependent
activated gene [24], that was significantly upregulated by both treatments with respect to IRI rats
(iPSC-EV, ≈19-fold increase and ASC-EV, ≈22-fold increase) (Figure 6d). Because sirtuins are known to
play major roles in protection against cellular stress and in controlling metabolic pathways [25], we
evaluated the expression of some members of the sirtuins family that are associated with biological
pathways overrepresented in the iPSC-EV-treated animals (Figure 6a,b). qRT-PCR analysis showed the
capability of only iPSC-EV to significantly up-regulate sirtuin 1 (SIRT1) (iPSC-EV, ≈2-fold increase and
ASC-EV, ≈1.5-fold increase, with respect to the IRI group) and sirtuin 2 (SIRT2) (iPSC-EV and ASC-EV,
≈1.5-fold increase, with respect to the IRI group) (Figure 6e,f, respectively). It is important to mention
that IRI promoted the downregulation of several genes associated with protection against ROS, such
as catalase (CAT), TXNRD2, peroxiredoxin 5 (PRDX5), SOD1, and SOD2 (Table S3).
Table 1. Genes modulated by iPSC-EV treatment during IRI and associated with oxidative stress in
renal tissue (iPSC-EV with respect to IRI).
Fold Change with
respect to IRI Symbol Gene Name Location
13.0 RAG2 recombination activating 2 Nucleus
8.6 NOXA1 NADPH oxidase activator 1 Plasma Membrane
3.5 UCP3 uncoupling protein 3 Cytoplasm
2.7 NGB neuroglobin Cytoplasm
2.1 Mpo myeloperoxidase Extracellular Space
1.8 Hba-a2/Hba1 hemoglobin, alpha 1 Cytoplasm
1.8 AOX1 aldehyde oxidase 1 Cytoplasm
1.8 DUOX2 dual oxidase 2 Plasma Membrane
1.7 GPX6 glutathione peroxidase 6 Extracellular Space
1.7 TPO thyroid peroxidase Plasma Membrane
1.7 SOD1 superoxide dismutase 1 Cytoplasm
1.6 NOX4 NADPH oxidase 4 Cytoplasm
1.6 ERCC6 ERCC excision repair 6,chromatin remodeling factor Nucleus
1.6 PTGS1 prostaglandin-endoperoxidesynthase 1 Cytoplasm
1.6 CYBA cytochrome b-245 alphachain Cytoplasm
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Table 1. Cont.
Fold Change with
respect to IRI Symbol Gene Name Location
1.6 CCL5 C-C motif chemokine ligand5 Extracellular Space
1.6 EHD2 EH domain containing 2 Nucleus
1.6 PSMB5 proteasome subunit beta 5 Cytoplasm
1.6 TXNRD2 thioredoxin reductase 2 Cytoplasm
1.5 SLC38A1 solute carrier family 38member 1 Plasma Membrane
1.5 SOD3 superoxide dismutase 3 Extracellular Space
1.5 EPX eosinophil peroxidase Cytoplasm
1.5 PARK7 Parkinsonism associateddeglycase Nucleus
1.5 TXN thioredoxin Cytoplasm
1.5 GSTK1 glutathione S-transferasekappa 1 Cytoplasm
−1.6 NOXO1 NADPH oxidase organizer 1 Plasma Membrane
−1.6 GSTP1 glutathione S-transferase pi 1 Cytoplasm
−1.8 GPX5 glutathione peroxidase 5 Extracellular Space
−1.9 ALB albumin Extracellular Space
−3.0 LPO lactoperoxidase Extracellular Space
−8.0 NOS2 nitric oxide synthase 2 Cytoplasm
−11.1 DUOX1 dual oxidase 1 Plasma Membrane
−11.4 MB myoglobin Cytoplasm
−21.5 HSPA1A/HSPA1B heat shock protein family A(Hsp70) member 1A Cytoplasm
4. Discussion
EV derived from stem cells have been shown to support tissue recovery, and investigations on
new sources of EV could bring therapeutic alternatives in the treatment of kidney diseases. The results
obtained in this work show, for the first time, that iPSC can be an interesting source of EV for treatment
of AKI, capable of reducing renal cell death, tissue damage, and macrophage infiltration, and of
ameliorating renal function. Part of iPSC-EV’s effects is associated with the protection of mitochondria
from IRI damage, maintaining a functional mitochondrial mass despite the injury. Comparing the
effects with ASC-EV, iPSC-EV presented similar beneficial properties and an even better outcome in the
reduction of cell death. Gene array analysis revealed that iPSC-EV mechanism of action was associated
with the regulation of key genes known to prevent damage caused by oxidative stress inside renal cells.
The therapeutic potential of MSC, along with their EV, has been the focus of several studies due to
their beneficial effects in the AKI model [26–28]. However, the restricted availability of MSC, as in the
cases of those derived from bone marrow, or the limited doubling properties, are limiting elements
in the translation to clinical applications. To overcome such limitations, different groups have used
MSC iPSC-derived as an alternative strategy for cellular therapy and as a source of EV in the treatment
of multiple diseases, including AKI [29–31]. Despite iPSC having been shown also to attenuate AKI,
no data have been presented on the therapeutic potential of EV secreted by these cells in kidney
injury. In our experimental protocol, we decided to cultivate iPSC in serum-free composition-defined
medium to guarantee the purity of the obtained EV and also to work in accordance with a perspective
of clinical application where the use of animal serum would represent a limitation in the use of EV
for the treatment. In our hands, iPSC secreted a heterogeneous population of EV, containing vesicles
of different sizes that corresponded to exosomes and microvesicle populations. Moreover, a deep
analysis in EV surface markers revealed that iPSC-EV carry several molecules that are associated with
the pluripotent state of iPSC, confirming that EV derived from iPSC compartmentalize molecules
from their cell of origin and are also of interest to some of their properties. Remarkably, among the
molecules highly present in iPSC-EV, CD326—epithelial cell adhesion molecule (EpCAM)—has been
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reported to be upregulated in renal epithelial cells after IRI and to play an important role in renal
regeneration [32]. Furthermore, CD133 (prominin-1) that is also carried by iPSC-EV has been described
as being expressed in renal resident cells after damage. The regulatory role of CD133 seems to be
mediated by Wnt/β-catenin signalling, inducing proliferation and limiting cell senescence [33]. Such
compartmentalized molecules can confer specificity in the beneficial actions mediated by iPSC-EV,
regulating key processes in renal recovery.
In order to evaluate iPSC-EV effects in the kidney, we performed a kidney subcapsular injection
to optimize the EV delivery, as once only a fraction of intravenously administrated EV reached the
kidney [34]. The administration of iPSC-EV just after the release of the vessel’s obstruction showed
that it can act in the prevention of tissue damage progression in the critical phase of the reperfusion,
instead of the recovery stage. In fact, the presence of EV administrated under the renal capsule could
be mainly detected in the first 24 h after injection, supporting the early actions of EV [15]. As a result of
iPSC-EV administration, the mitochondrial mass of renal cells was maintained, and more importantly,
also the ∆Ψm. The ∆Ψm is an important element of energy mitochondrial storage that is used to
generate ATP, and prolonged perturbation of its stability can result in loss of cell viability and trigger
the pathological processes associated with oxidative stress [35]. The reduction of ATP intracellular
levels provoked by chemical anoxia was partially reversed by the presence of ASC-EV, resulting in
cell death protection [18]. Moreover, iPSC-EV showed a more efficient result in renal cell protection
when compared to ASC-EV, although both EV presented similar responses in the maintenance of
mitochondria mass and the ∆Ψm. This data indicates that other elements, besides mitochondria
protection, can be involved in renal cell death reduction promoted by iPSC-EV.
The role of iPSC-EV in renal tissue has also been associated with the modulation of the
immune response. During AKI, circulating monocytes can be recruited to the kidney by secreted
chemokines derived from the damaged tissue and differentiate into proinflammatory macrophages.
The macrophages can increase reactive oxygen species generation and the apoptotic death rate of
renal tubular cells [36]. Similarly, systemic depletion monocytes and macrophages prior to IRI
attenuate morphologic kidney damage and partially re-establish the BUN and creatinine levels in the
blood [37,38]. A similar response was obtained by the administration of iPSC-EV, resulting in the
reduction of macrophage infiltration and the protection of renal function characterized by the reduced
levels of BUN and creatinine in the blood. Interestingly, together with the reduction of macrophage
infiltration, iPSC-EV administration led to an increase in the CD206 expression in renal tissue. CD206
is a marker of M2 macrophages, and such polarization has been described as occurring during the
resolution phase of AKI, characterized by immunosuppression and tissue regeneration [39]. In this
manner, iPSC-EV are capable of modulating the inflammatory environment and therefore promoting,
also through this mechanism, the reduction of renal tissue damage.
Because mitochondria are mainly responsible for the intracellular ROS production during the
reperfusion phase of IRI [40], and because the presence of iPSC-EV was shown to promote the
protection of mitochondria, further investigation revealed that the mechanism associated with the
beneficial effect of iPSC-EV is extended to the regulation of oxidative stress. Administration of
iPSC-EV resulted in the modulation of several genes in the renal tissue associated with the protection
against oxidative stress (SOD1, SOD3, SEPP1, TXN1, TXNRD2, GSTK1), and IPA analysis revealed
that iPSC-EV regulated different cellular processes such as NRF2-mediated responses, superoxide
radical degradation, mitochondrial dysfunction, production of nitric oxide, and reactive oxygen species
in macrophages. The SODs are a group of enzymes responsible for catalyzing the conversion of
superoxide into oxygen and hydrogen peroxide, and iPSC-EV promotes the increase of mRNA levels
of SOD1 and SOD3. The enzyme Sod1 is an important scavenger protein localized in the cytosol
that acts against the oxidative stress by catalyzing the conversion of superoxide anion to hydrogen
peroxide (H2O2). Posteriorly, the H2O2 can be reduced to water by other enzymes such as glutathione
peroxidase or catalase [41]. Although the precise role of Sod3 requires further investigation, it is the
most widely expressed isoform in the kidney and, therefore, it has an important role in the protection
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against oxidative stress during IRI [42]. In addition, Sod3 was reported to be a regulator of vascular
function and is associated with the maintenance of renal blood flow after IRI [43].
The thioredoxin system seems to participate in the anti-ROS action modulated by iPSC-EV. Such a
system is composed of ubiquitous thiol oxidoreductases that regulate cellular redox status [44]. In our
model, iPSC-EV were shown to upregulate the expression of TXN1 and TXNRD2. Txn1 is a cytoplasmic
enzyme and has been described to protect the kidney from oxidative stress, and overexpression
of Txn1 resulted in the attenuation of the damage by IRI [44,45]. Txnrd2 is known to be an H2O2
scavenger and is responsible for maintaining the redox homeostasis by eliminating H2O2 and preserving
mitochondria integrity [46]. In addition, Gstk1 is also another anti-ROS enzyme-modulated gene by
iPSC-EV administration that is present in the mitochondria and possesses glutathione-conjugating
activity towards halogenated aromatics [47,48] and, therefore, contributes to the reduction of the
renal damage given by IRI. Another pro-regenerative molecule induced by iPSC-EV treatment is
Sepp1, an extracellular glycoprotein that presents a dual role as a selenium supplier for the renal
tissue and as an antioxidant, regulating late ROS accumulation [49]. Moreover, iPSC-EV treatment
was also found to be able to induce the expression of SIRT1 and SIRT2, two members of the Sir2
(silent information regulator 2) family, a group of class III deacetylases. Sirtuins, whose pathway was
overrepresented by the iPSC-EV treatment, are involved in cellular energy metabolism and control
of the redox state [25]. In the kidneys, SIRT1 has been described as inhibiting renal cell apoptosis,
inflammation, and fibrosis, and may regulate lipid metabolism, autophagy, blood pressure, and sodium
balance [50]. iPSC-EV treatment can reduce some oxidative stress sensors such as iNOS, NOXO1,
LPO, and DUOX1. Interestingly, it has been previously reported that post-AKI rats had an increased
expression of other pro-oxidant genes such as LPO, myeloperoxidase, and DUOX1 [51]. Moreover,
gene set enrichment analyses in IRI condition revealed that high DUOX1 expression is significantly
correlated with the enrichment of immune pathways related to interferon (IFN)-alpha, IFN-gamma,
and natural killer (NK) cell signalling [52].
Taken the data together, IPSC-EV were shown to be capable of acting on critical points of AKI,
in terms of oxidative stress, inflammation, and cell death. Such properties show a new relevant
application of iPSC in the treatment of kidney diseases, bypassing the risks associated with the use of
the cell itself. In addition, iPSC can be explored as a new source of EV due to its properties associated
with long-term survival, homogenous cell population, and high and fast expansion, that are known to
be limited in MSC and critical under a therapeutic perspective [53]. Further studies investigating the
entire composition of iPSC-EV would be valuable in better understanding their safety and potential in
tissue regeneration as a therapeutic tool.
5. Conclusions
This work shows that iPSC-EV have a protective role in kidney IRI, acting in different aspects
associated with tissue damage. Gene array analysis revealed that the main mechanisms associated with
the beneficial effects of iPSC-EV is based on the protection of mitochondria, as well as reduction of
oxidative stress and inflammation. Administration of iPSC-EV presented as similar or in some aspects
higher efficiency in the kidney protection when compared to ASC-EV. Therefore, iPSC can be considered as
an alternative source of EV with therapeutic properties to be explored for the treatment of kidney diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/2/453/s1,
Table S1: Raw data of oxidative stress gene arrays from renal tissue in the different experimental conditions in the
in vivo model. Table S2:. List of the primers used in the qRT-PCR analysis. Table S3: Modulated genes associated
with oxidative stress in renal tissue, modulated by IRI (SHAM with respect to IRI).
Author Contributions: Conceptualization, F.C., B.B., A.V., and R.S.L.; methodology, F.C., M.T., G.G.T., T.H.K.-B.,
R.S., C.H.C.W., K.R.d.M., B.B., and R.S.L.; software, F.C., M.T., R.S., C.H.C.W., K.R.d.M., and R.S.L.; validation,
F.C., M.T., G.G.T., T.H.K., and R.S.L.; formal analysis, F.C., M.T., R.S., C.H.C.W., K.R.d.M., and R.S.L.; investigation,
F.C., J.A.L., M.T., G.M.C.L., D.B.A., and R.S.L.; resources, B.B., A.V., and R.S.L.; writing—original draft preparation,
F.C., B.B., A.V., and R.S.L.; writing—review and editing, F.C., B.B., A.V., and R.S.L.; signalling, F.C. and R.S.L.;
Cells 2020, 9, 453 18 of 20
supervision, F.C., B.B., A.V., and R.S.L.; project administration, F.C., B.B., A.V., and R.S.L.; funding acquisition,
F.C., B.B., A.V., and R.S.L. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by the National Institute of Science and Technology for Regenerative Medicine
REGENERA (grant number 465656/2014-5); the Brazilian National Research Council (grant numbers 421916/2016-8,
404092/2012-8, 457222/2013-1, 403151/2015-5, 307605/2015-9); the Carlos Filho Rio de Janeiro State Research
Foundation (grant numbers E-26/201.142/2014, E-26/010.001283/2015); MIUR-local Research to B.B. and starting
grant (COLL_AFAR19_01)—DSB, Padova to F.C.; and the European Union’s Horizon 2020 research and innovation
program under the Marie Skłodowska-Curie grant agreement no. 813839, project RenalToolBox.
Acknowledgments: We acknowledge Prof. Robson de Queiroz Monteiro from the Institute of Medical
Biochemistry—UFRJ, for the availability of the instrument ZetaView for the particle analyses. We also acknowledge
Federica Antico for the technical support in the preparation and staining of the tissue slides. We further
acknowledge the access to the facilities at the National Center of Structural Biology and Bioimaging-CENABIO,
Federal University of Rio de Janeiro.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Peired, A.J.; Sisti, A.; Romagnani, P. Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review
of Clinical Evidence. Stem Cells Int. 2016, 2016, 4798639. [CrossRef] [PubMed]
2. Yasuda, S.; Kusakawa, S.; Kuroda, T.; Miura, T.; Tano, K.; Takada, N.; Matsuyama, S.; Matsuyama, A.;
Nasu, M.; Umezawa, A.; et al. Tumorigenicity-associated characteristics of human iPS cell lines. PLoS ONE.
2018, 13, e0205022. [CrossRef] [PubMed]
3. Tögel, F.; Zhang, P.; Hu, Z.; Westenfelder, C. VEGF is a mediator of the renoprotective effects of multipotent
marrow stromal cells in acute kidney injury. J. Cell Mol. Med. 2009, 13, 2109–2114. [CrossRef] [PubMed]
4. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and
other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30, 255–289. [CrossRef] [PubMed]
5. Yáñez-Mó, M.; Siljander, P.R.; Andreu, Z.; Zavec, A.B.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.;
Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell
Vesicles 2015, 4, 27066. [CrossRef]
6. Bruno, S.; Bussolati, B.; Grange, C.; Collino, F.; di Cantogno, L.V.; Herrera, M.B.; Biancone, L.; Tetta, C.;
Segoloni, G.; Camussi, G. Isolation and characterization of resident mesenchymal stem cells in human
glomeruli. Stem Cells Dev. 2009, 18, 867–880. [CrossRef]
7. Lindoso, R.S.; Collino, F.; Bruno, S.; Araujo, D.S.; Sant’Anna, J.F.; Tetta, C.; Provero, P.; Quesenberry, P.J.; Vieyra, A.;
Einicker-Lamas, M.; et al. Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in
renal tubular cells and inhibit ATP depletion injury. Stem Cells Dev. 2014, 23, 1809–1819. [CrossRef]
8. Lindoso, R.S.; Lopes, J.A.; Binato, R.; Abdelhay, E.; Takiya, C.M.; Miranda, K.R.; Lara, L.S.; Viola, A.;
Bussolati, B.; Vieyra, A.; et al. Adipose mesenchymal cells-derived EVs alleviate DOCA-salt-induced
hypertension by promoting cardio-renal protection. Mol. Ther. Methods Clin. Dev. 2019, 16, 63–77. [CrossRef]
9. Grange, C.; Tritta, S.; Tapparo, M.; Cedrino, M.; Tetta, C.; Camussi, G.; Brizzi, M.F. Stem cell-derived
extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy.
Sci. Rep. 2019, 9, 4468. [CrossRef]
10. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell 2006, 126, 663–676. [CrossRef]
11. Martin, U. Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks. Front. Med. 2017, 4,
229. [CrossRef] [PubMed]
12. Lee, P.Y.; Chien, Y.; Chiou, G.Y.; Lin, C.H.; Chiou, C.H.; Tarng, D.C. Induced pluripotent stem cells without
c-Myc attenuate acute kidney injury via downregulating the signaling of oxidative stress and inflammation
in ischemia-reperfusion rats. Cell Transplant. 2012, 21, 2569–2585. [CrossRef] [PubMed]
13. Wang, Y.; Zhang, L.; Li, Y.; Chen, L.; Wang, X.; Guo, W.; Zhang, X.; Qin, G.; He, S.H.; Zimmerman, A.; et al.
Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent
cardiomyocyte apoptosis in the ischemic myocardium. Int. J. Cardiol. 2015, 192, 61–69. [CrossRef] [PubMed]
14. Sochacki, J.; Devalle, S.; Reis, M.; Mattos, P.; Rehen, S. Generation of urine iPS cell lines from patients with
Attention Deficit Hyperactivity Disorder (ADHD) using a non-integrative method. Stem Cell Res. 2016, 17,
102–106. [CrossRef]
Cells 2020, 9, 453 19 of 20
15. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of
pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [CrossRef]
16. Kasai-Brunswick, T.H.; Silva Dos Santos, D.; Ferreira, R.P.; Araujo, D.S.; Dias, G.M.; Coutinho, J.L.A.;
Cruz, F.E.S.F.; Sternick, E.B.; Gubert, F.; Oliveira, J.C.G.; et al. Generation of patient-specific induced
pluripotent stem cell lines from one patient with Jervell and Lange-Nielsen syndrome, one with type 1 long
QT syndrome and two healthy relatives. Stem Cell Res. 2018, 31, 174–180. [CrossRef]
17. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.;
Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018
(MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the
MISEV2014 guidelines. J Extracell. Vesicles 2018, 7, 1535750. [CrossRef]
18. Collino, F.; Lopes, J.A.; Corrêa, S.; Abdelhay, E.; Takiya, C.M.; Wendt, C.H.C.; de Miranda, K.R.; Vieyra, A.;
Lindoso, R.S. Adipose-Derived Mesenchymal Stromal Cells Under Hypoxia: Changes in Extracellular
Vesicles Secretion and Improvement of Renal Recovery after Ischemic Injury. Cell Physiol. Biochem. 2019, 52,
1463–1483.
19. Bruno, S.; Pasquino, C.; Herrera Sanchez, M.B.; Tapparo, M.; Figliolini, F.; Grange, C.; Chiabotto, G.;
Cedrino, M.; Deregibus, M.C.; Tetta, C.; et al. HLSC-derived extracellular vesicles attenuate liver fibrosis and
inflammation in a murine model of non-alcoholic steatohepatitis. Mol. Ther. 2020, 28, 479–489. [CrossRef]
20. Bruno, S.; Grange, C.; Deregibus, M.C.; Calogero, R.A.; Saviozzi, S.; Collino, F.; Morando, L.; Busca, A.;
Falda, M.; Bussolati, B.; et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular
injury. J. Am. Soc. Nephrol. 2009, 20, 1053–1067. [CrossRef]
21. Yamanaka, S. A fresh look at iPS cells. Cell. 2009, 137, 13–17. [CrossRef] [PubMed]
22. Lemasters, J.J.; Nieminen, A.L.; Qian, T.; Trost, L.C.; Elmore, S.P.; Nishimura, Y.; Crowe, R.A.; Cascio, W.E.;
Bradham, C.A.; Brenner, D.A.; et al. The mitochondrial permeability transition in cell death: A common
mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1998, 1366, 177–196. [CrossRef]
23. Martin, J.L.; Gruszczyk, A.V.; Beach, T.E.; Murphy, M.P.; Saeb-Parsy, K. Mitochondrial mechanisms and
therapeutics in ischaemia reperfusion injury. Pediatr. Nephrol. 2019, 34, 1167–1174. [CrossRef]
24. Maeda, K.; Ohno, T.; Igarashi, S.; Yoshimura, T.; Yamashiro, K.; Sakai, M. Aldehyde oxidase 1 gene is
regulated by Nrf2 pathway. Gene 2012, 505, 374–378. [CrossRef] [PubMed]
25. Poulose, N.; Raju, R. Sirtuin regulation in aging and injury. Biochim. Biophys. Acta 2015, 1852, 2442–2455.
[CrossRef] [PubMed]
26. Bruno, S.; Tapparo, M.; Collino, F.; Chiabotto, G.; Deregibus, M.C.; Soares Lindoso, R.; Neri, F.; Kholia, S.;
Giunti, S.; Wen, S.; et al. Renal Regenerative Potential of Different Extracellular Vesicle Populations Derived
from Bone Marrow Mesenchymal Stromal Cells. Tissue Eng. Part A 2017, 23, 1262–1273. [CrossRef]
27. Yagi, H.; Soto-Gutierrez, A.; Kitagawa, Y.; Tilles, A.W.; Tompkins, R.G.; Yarmush, M.L. Bone marrow
mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant. 2010, 19,
823–830. [CrossRef]
28. Herrera, M.B.; Bussolati, B.; Bruno, S.; Morando, L.; Mauriello-Romanazzi, G.; Sanavio, F.; Stamenkovic, I.;
Biancone, L.; Camussi, G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44
following acute tubular injury. Kidney Int. 2007, 72, 430–441. [CrossRef]
29. Luzzani, C.D.; Miriuka, S.G. Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells. Stem
Cell Rev. Rep. 2017, 13, 68–78. [CrossRef]
30. Yuan, X.; Li, D.; Chen, X.; Han, C.; Xu, L.; Huang, T.; Dong, Z.; Zhang, M. Extracellular vesicles from
human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against
renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of
sphingosine kinase 1 and inhibiting necroptosis. Cell Death Dis. 2017, 8, 3200.
31. Sheyn, D.; Ben-David, S.; Shapiro, G.; De Mel, S.; Bez, M.; Ornelas, L.; Sahabian, A.; Sareen, D.; Da, X.;
Pelled, G.; et al. Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells
and repair bone defects. Stem Cells Transl. Med. 2016, 5, 1447–1460. [CrossRef] [PubMed]
32. Trzpis, M.; McLaughlin, P.M.; van Goor, H.; Brinker, M.G.; van Dam, G.M.; de Leij, L.M.; Popa, E.R.;
Harmsen, M.C. Expression of EpCAM is up-regulated during regeneration of renal epithelia. J. Pathol. 2008,
216, 201–208. [CrossRef] [PubMed]
33. Brossa, A.; Papadimitriou, E.; Collino, F.; Incarnato, D.; Oliviero, S.; Camussi, G.; Bussolati, B. Role of CD133
molecule in Wnt response and renal repair. Stem Cells Transl. Med. 2018, 7, 283–294. [CrossRef] [PubMed]
Cells 2020, 9, 453 20 of 20
34. Grange, C.; Tapparo, M.; Bruno, S.; Chatterjee, D.; Quesenberry, P.J.; Tetta, C.; Camussi, G. Biodistribution of
mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical
imaging. Int. J. Mol. Med. 2014, 33, 1055–1063. [CrossRef]
35. Izyumov, D.S.; Avetisyan, A.V.; Pletjushkina, O.Y.; Sakharov, D.V.; Wirtz, K.W.; Chernyak, B.V.; Skulachev, V.P.
“Wages of fear”: Transient threefold decrease in intracellular ATP level imposes apoptosis. Biochim. Biophys.
Acta 2004, 1658, 141–147. [CrossRef]
36. Cao, Q.; Harris, D.C.; Wang, Y. Macrophages in kidney injury, inflammation, and fibrosis. Physiology 2015,
30, 183–194. [CrossRef]
37. Jo, S.K.; Sung, S.A.; Cho, W.Y.; Go, K.J.; Kim, H.K. Macrophages contribute to the initiation of ischaemic
acute renal failure in rats. Nephrol. Dial. Transplant. 2006, 21, 1231–1239. [CrossRef]
38. Day, Y.J.; Huang, L.; Ye, H.; Linden, J.; Okusa, M.D. Renal ischemia-reperfusion injury and adenosine 2A
receptor-mediated tissue protection: Role of macrophages. Am. J. Physiol. Renal Physiol. 2005, 288, F722–F731.
[CrossRef]
39. Chen, T.; Cao, Q.; Wang, Y.; Harris, D.C.H. M2 macrophages in kidney disease: Biology, therapies, and
perspectives. Kidney Int. 2019, 95, 760–773. [CrossRef]
40. Granger, D.N.; Kvietys, P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept.
Redox Biol. 2015, 6, 524–551. [CrossRef]
41. Fridovich, I. Superoxide radical and superoxide dismutases. Annu. Rev. Biochem. 1995, 64, 97–112. [CrossRef]
[PubMed]
42. Schneider, M.P.; Sullivan, J.C.; Wach, P.F.; Boesen, E.I.; Yamamoto, T.; Fukai, T.; Harrison, D.G.; Pollock, D.M.;
Pollock, J.S. Protective role of extracellular superoxide dismutase in renal ischemia/reperfusion injury. Kidney
Int. 2010, 78, 374–381. [CrossRef] [PubMed]
43. Strålin, P.; Karlsson, K.; Johansson, B.O.; Marklund, S.L. The interstitium of the human arterial wall contains
very large amounts of extracellular superoxide dismutase. Arterioscler. Thromb. Vasc. Biol. 1995, 15,
2032–2036. [CrossRef] [PubMed]
44. Kasuno, K.; Nakamura, H.; Ono, T.; Muso, E.; Yodoi, J. Protective roles of thioredoxin, a redox-regulating
protein, in renal ischemia/reperfusion injury. Kidney Int. 2003, 64, 1273–1282. [CrossRef] [PubMed]
45. Kim, Y.C.; Masutani, H.; Yamaguchi, Y.; Itoh, K.; Yamamoto, M.; Yodoi, J. Hemin-induced activation of the
thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding
factors. J. Biol. Chem. 2001, 276, 18399–18406. [CrossRef] [PubMed]
46. Kiermayer, C.; Northrup, E.; Schrewe, A.; Walch, A.; de Angelis, M.H.; Schoensiegel, F.; Zischka, H.; Prehn, C.;
Adamski, J.; Bekeredjian, R.; et al. Heart-Specific Knockout of the Mitochondrial Thioredoxin Reductase
(Txnrd2) Induces metabolic and contractile dysfunction in the aging myocardium. J. Am. Heart Assoc. 2015,
4, pii: e002153. [CrossRef]
47. Marí, M.; Morales, A.; Colell, A.; García-Ruiz, C.; Fernández-Checa, J.C. Mitochondrial glutathione, a key
survival antioxidant. Antioxid. Redox Signal. 2009, 11, 2685–2700. [CrossRef]
48. Morel, F.; Aninat, C. The glutathione transferase kappa family. Drug Metab. Rev. 2011, 43, 281–291. [CrossRef]
49. Burk, R.F.; Hill, K.E. Selenoprotein P-expression, functions, and roles in mammals. Biochim. Biophys. Acta
2009, 1790, 1441–1447. [CrossRef]
50. Kitada, M.; Kume, S.; Takeda-Watanabe, A.; Kanasaki, K.; Koya, D. Sirtuins and renal diseases: Relationship
with aging and diabetic nephropathy. Clin. Sci. 2013, 124, 153–164. [CrossRef]
51. Basile, D.P.; Leonard, E.C.; Beal, A.G.; Schleuter, D.; Friedrich, J. Persistent oxidative stress following renal
ischemia-reperfusion injury increases ANG II hemodynamic and fibrotic activity. Am. J. Physiol. Renal
Physiol. 2012, 302, F1494–F1502. [CrossRef] [PubMed]
52. Cho, S.Y.; Kim, S.; Son, M.J.; Kim, G.; Singh, P.; Kim, H.N.; Choi, H.G.; Yoo, H.J.; Ko, Y.B.; Lee, B.S.; et al. Dual
oxidase 1 and NADPH oxidase 2 exert favorable effects in cervical cancer patients by activating immune
response. BMC Cancer 2019, 19, 1078. [CrossRef] [PubMed]
53. Lavon, N.; Zimerman, M.; Itskovitz-Eldor, J. Scalable expansion of pluripotent stem cells. Adv. Biochem. Eng.
Biotechnol. 2018, 163, 23–37. [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
